Form 4: Indivior CLO Burris Reports Significant Equity Grants

Indivior Pharmaceuticals' Chief Legal Officer, Jeffrey W. Burris, reported the grant of restricted stock units and performance stock units.

Summary

• Jeffrey W. Burris, Chief Legal Officer of Indivior Pharmaceuticals, Inc., reported the acquisition of 26,897 shares of common stock on February 10, 2026, reflecting a grant of Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of common stock per unit, vesting in three equal annual installments beginning February 10, 2027, contingent on continued service.
• Burris also reported the acquisition of 104,300 Performance Stock Units (PSUs) on February 9, 2026.
• These PSUs were a conditional award granted on March 3, 2023, with performance conditions certified on February 9, 2026, and are set to vest on March 3, 2026, subject to continued employment.
• Following these transactions, Burris beneficially owns 27,657 shares of common stock and 104,300 derivative securities (PSUs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard executive compensation disclosure, reflecting the company's ongoing incentive programs. The grants tie executive performance to shareholder value, which is generally positive for corporate governance.

Positives

• The grants of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) align management's interests with long-term shareholder value.
• The vesting schedules for both RSUs (three equal annual installments) and PSUs (vesting on March 3, 2026) incentivize continued service and performance.

Risks

• The vesting of RSUs and PSUs is subject to the reporting person's continued service and, for PSUs, satisfaction of performance conditions, meaning the full value is not guaranteed if conditions are not met or employment ceases.

Future Outlook

The vesting schedules for the granted equity awards extend into 2026 and 2027, indicating a long-term incentive structure for the Chief Legal Officer.

Management Comments

• The grant of restricted stock units reflects a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, subject to the Reporting Person's continued service with the Issuer.
• The conditional award for 104,300 shares, subject to satisfaction of performance conditions, was certified on February 9, 2026, and vests, subject to continued employment conditions, on March 3, 2026.

Industry Context

StockSavvy.ai notes that equity grants to senior executives like Chief Legal Officers are a standard practice across industries, serving as a key component of executive compensation packages designed to align executive incentives with shareholder interests and promote long-term retention and performance.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Grant of 26,897 Restricted Stock Units (RSUs) to Chief Legal Officer Jeffrey W. Burris.
• Grant of 104,300 Performance Stock Units (PSUs) to Chief Legal Officer Jeffrey W. Burris.
• Execution of a Power of Attorney by Jeffrey W. Burris, authorizing company personnel (including himself, Alice Givens, and David Wisniewski) to file SEC forms on his behalf.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Legal Officer's financial interests with the long-term performance of Indivior Pharmaceuticals, potentially benefiting shareholders through incentivized executive performance.
• Employees: The grants demonstrate the company's commitment to executive compensation and retention, which can positively influence overall employee morale and retention strategies.

Next Steps

• Continued service by Jeffrey W. Burris to ensure vesting of RSUs and PSUs.
• Future vesting of 26,897 RSUs in three equal annual installments starting February 10, 2027.
• Vesting of 104,300 PSUs on March 3, 2026, subject to continued employment.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation through equity grants. While these grants align management incentives with shareholder interests, they do not present new information that would fundamentally alter the investment thesis for Indivior Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Indivior Pharmaceuticals, INDV, Jeffrey W. Burris, Chief Legal Officer, SEC Form 4, Insider Trading, Restricted Stock Units, Performance Stock Units, Equity Grant, Executive Compensation